{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:38:20Z","timestamp":1785839900186,"version":"3.56.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzhen","doi-asserted-by":"crossref","award":["SZSM202411022"],"award-info":[{"award-number":["SZSM202411022"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010877","name":"Shenzhen Science and Technology Innovation Commission","doi-asserted-by":"crossref","award":["JCYJ20230807110659001"],"award-info":[{"award-number":["JCYJ20230807110659001"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06940-2","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T08:19:27Z","timestamp":1774253967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["FTO\u2013CHRM3 axis regulates multiple myeloma progression: a machine learning-based identification"],"prefix":"10.1007","volume":"105","author":[{"given":"Bo","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Bin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Fei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Tian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"6940_CR1","doi-asserted-by":"publisher","first-page":"101465","DOI":"10.1016\/j.tranon.2022.101465","volume":"22","author":"Y Li","year":"2022","unstructured":"Li Y, Sun Z, Qu X (2022) Advances in the treatment of extramedullary disease in multiple myeloma. Transl Oncol 22:101465. https:\/\/doi.org\/10.1016\/j.tranon.2022.101465","journal-title":"Transl Oncol"},{"key":"6940_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41419-023-06036-z","volume":"14","author":"Y Jia","year":"2023","unstructured":"Jia Y, Yu X, Liu R et al (2023) PRMT1 methylation of WTAP promotes multiple myeloma tumorigenesis by activating oxidative phosphorylation via m6A modification of NDUFS6. Cell Death Dis 14:512. https:\/\/doi.org\/10.1038\/s41419-023-06036-z","journal-title":"Cell Death Dis"},{"key":"6940_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s12032-019-1260-6","volume":"36","author":"G Tuncel","year":"2019","unstructured":"Tuncel G, Kalkan R (2019) Importance of m N6-methyladenosine (m6A) RNA modification in cancer. Med Oncol 36:36. https:\/\/doi.org\/10.1007\/s12032-019-1260-6","journal-title":"Med Oncol"},{"key":"6940_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41392-020-00450-x","volume":"6","author":"X Jiang","year":"2021","unstructured":"Jiang X, Liu B, Nie Z et al (2021) The role of m6A modification in the biological functions and diseases. Signal Transduct Target Ther 6:74. https:\/\/doi.org\/10.1038\/s41392-020-00450-x","journal-title":"Signal Transduct Target Ther"},{"key":"6940_CR5","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1016\/j.gendis.2022.04.014","volume":"10","author":"C Huang","year":"2023","unstructured":"Huang C, Chen W, Wang X (2023) Studies on the fat mass and obesity-associated (FTO) gene and its impact on obesity-associated diseases. Genes Dis 10:2351\u20132365. https:\/\/doi.org\/10.1016\/j.gendis.2022.04.014","journal-title":"Genes Dis"},{"key":"6940_CR6","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.ymthe.2021.12.012","volume":"30","author":"A Xu","year":"2022","unstructured":"Xu A, Zhang J, Zuo L et al (2022) FTO promotes multiple myeloma progression by posttranscriptional activation of HSF1 in an m6A-YTHDF2-dependent manner. Mol Ther 30:1104\u20131118. https:\/\/doi.org\/10.1016\/j.ymthe.2021.12.012","journal-title":"Mol Ther"},{"key":"6940_CR7","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/s41417-022-00429-6","volume":"30","author":"C Wang","year":"2023","unstructured":"Wang C, Li L, Li M et al (2023) FTO promotes Bortezomib resistance via m6A-dependent destabilization of SOD2 expression in multiple myeloma. Cancer Gene Ther 30:622\u2013628. https:\/\/doi.org\/10.1038\/s41417-022-00429-6","journal-title":"Cancer Gene Ther"},{"key":"6940_CR8","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1182\/blood.2019004263","volume":"138","author":"Y Qing","year":"2021","unstructured":"Qing Y, Su R, Chen J (2021) RNA modifications in hematopoietic malignancies: a new research frontier. Blood 138:637\u2013648. https:\/\/doi.org\/10.1182\/blood.2019004263","journal-title":"Blood"},{"key":"6940_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13045-024-01546-5","volume":"17","author":"G Feng","year":"2024","unstructured":"Feng G, Wu Y, Hu Y et al (2024) Small molecule inhibitors targeting m6A regulators. J Hematol Oncol 17:30. https:\/\/doi.org\/10.1186\/s13045-024-01546-5","journal-title":"J Hematol Oncol"},{"key":"6940_CR10","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1080\/15384101.2023.2170521","volume":"22","author":"C-J Chen","year":"2023","unstructured":"Chen C-J, Huang J-Y, Huang J-Q et al (2023) Metformin attenuates multiple myeloma cell proliferation and encourages apoptosis by suppressing METTL3-mediated m6A methylation of THRAP3, RBM25, and USP4. Cell Cycle 22:986\u20131004. https:\/\/doi.org\/10.1080\/15384101.2023.2170521","journal-title":"Cell Cycle"},{"key":"6940_CR11","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.11817\/j.issn.1672-7347.2023.220534","volume":"48","author":"C Hu","year":"2023","unstructured":"Hu C, Kuang C, Zhou W (2023) Advances in the pathogenesis of multiple myeloma bone disease. Zhong Nan Da Xue Xue Bao Yi Xue Ban 48:1403\u20131410. https:\/\/doi.org\/10.11817\/j.issn.1672-7347.2023.220534","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"6940_CR12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13287-021-02223-x","volume":"12","author":"H Luo","year":"2021","unstructured":"Luo H, Liu W, Zhang Y et al (2021) METTL3-mediated m6A modification regulates cell cycle progression of dental pulp stem cells. Stem Cell Res Ther 12:159. https:\/\/doi.org\/10.1186\/s13287-021-02223-x","journal-title":"Stem Cell Res Ther"},{"key":"6940_CR13","doi-asserted-by":"publisher","unstructured":"Wu R, Liu Y, Yao Y et al (2018) FTO regulates adipogenesis by controlling cell cycle progression via m6A-YTHDF2 dependent mechanism. Biochim Biophys Acta (BBA) -. Mol Cell Biol Lipids 1863:1323\u20131330. https:\/\/doi.org\/10.1016\/j.bbalip.2018.08.008","DOI":"10.1016\/j.bbalip.2018.08.008"},{"key":"6940_CR14","doi-asserted-by":"publisher","first-page":"90501","DOI":"10.18632\/oncotarget.18765","volume":"8","author":"A Maes","year":"2017","unstructured":"Maes A, Menu E, Veirman KD et al (2017) The therapeutic potential of cell cycle targeting in multiple myeloma. Oncotarget 8:90501\u201390520. https:\/\/doi.org\/10.18632\/oncotarget.18765","journal-title":"Oncotarget"},{"key":"6940_CR15","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3390\/cancers13020216","volume":"13","author":"T Hideshima","year":"2021","unstructured":"Hideshima T, Anderson KC (2021) Signaling Pathway Mediating Myeloma Cell Growth and Survival. Cancers 13:216. https:\/\/doi.org\/10.3390\/cancers13020216","journal-title":"Cancers"},{"key":"6940_CR16","doi-asserted-by":"publisher","first-page":"917","DOI":"10.32604\/or.2023.030425","volume":"31","author":"B Zhang","year":"2023","unstructured":"Zhang B, Zhao J, Wang Y et al (2023) CHRM3 is a novel prognostic factor of poor prognosis and promotes glioblastoma progression via activation of oncogenic invasive growth factors. Oncol Res 31:917\u2013927. https:\/\/doi.org\/10.32604\/or.2023.030425","journal-title":"Oncol Res"},{"key":"6940_CR17","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3390\/cancers3010971","volume":"3","author":"EC Von Rosenvinge","year":"2011","unstructured":"Von Rosenvinge EC, Raufman J-P (2011) Muscarinic Receptor Signaling in Colon Cancer. Cancers 3:971\u2013981. https:\/\/doi.org\/10.3390\/cancers3010971","journal-title":"Cancers"},{"key":"6940_CR18","doi-asserted-by":"publisher","first-page":"100741","DOI":"10.1016\/j.blre.2020.100741","volume":"46","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, Sun F, D\u2019Souza A et al (2021) Autonomic nervous system control of multiple myeloma. Blood Rev 46:100741. https:\/\/doi.org\/10.1016\/j.blre.2020.100741","journal-title":"Blood Rev"},{"key":"6940_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s43556-024-00188-w","volume":"5","author":"Q Lu","year":"2024","unstructured":"Lu Q, Yang D, Li H et al (2024) Multiple myeloma: signaling pathways and targeted therapy. Mol Biomed 5:25. https:\/\/doi.org\/10.1186\/s43556-024-00188-w","journal-title":"Mol Biomed"},{"key":"6940_CR20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3892\/ol.2022.13228","volume":"23","author":"L Meng","year":"2022","unstructured":"Meng L, Gu G, Bi L (2022) Transient receptor potential channels in multiple myeloma. Oncol Lett 23:108. https:\/\/doi.org\/10.3892\/ol.2022.13228","journal-title":"Oncol Lett"},{"key":"6940_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.18632\/oncotarget.109","volume":"1","author":"YN Demchenko","year":"2010","unstructured":"Demchenko YN, Kuehl WM (2010) A critical role for the NFkB pathway in multiple myeloma. Oncotarget 1:59\u201368. https:\/\/doi.org\/10.18632\/oncotarget.109","journal-title":"Oncotarget"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06940-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06940-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06940-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:58:26Z","timestamp":1776405506000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06940-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":21,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6940"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06940-2","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"21 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants were reviewed and approved by The Seventh Affiliated Hospital, Sun Yat-Sen University (Approval No. KY-2025-438-01). Written informed consent to participate in this study was provided by the participants. The study protocols adhered strictly to the principles outlined in the Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"201"}}